TALS Talaris Therapeutics

Talaris Therapeutics, Inc. (NASDAQ:TALS) Short Interest Up 22.5% in November

Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 703,800 shares, a growth of 22.5% from

12-01 05:01 ET

State Board of Administration of Florida Retirement System Makes New $64,000 Investment in Talaris Therapeutics, Inc. (NASDAQ:TALS)

State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its mos

11-23 05:51 ET

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

11-22 07:05 ET

Talaris Therapeutics (TALS) Gets a Hold From SVB Securities

11-13 11:00 ET

Talaris Therapeutics (NASDAQ:TALS) Trading 7% Higher

Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating)'s share price rose 7% during trading on Thursday . The stock traded as high as $1.57 and last traded at $1.53. Approximately 200,841 shares were

11-11 02:21 ET

Talaris Therapeutics Q3 EPS $(0.46) Down From $(0.32) YoY

Talaris Therapeutics (NASDAQ:TALS) reported quarterly losses of $(0.46) per share. This is a 43.75 percent decrease over losses of $(0.32) per share from the same period last year.

11-10 07:10 ET

Earnings Flash (TALS) TALARIS THERAPEUTICS Posts Q3 Loss $-0.46

11-10 07:05 ET

Press Release: Talaris Therapeutics Announces -2-

=== ================ =============== Net loss per common share, basic and diluted $ (0.46) $ (0.32) -

11-10 07:03 ET

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transfo

11-07 07:07 ET

HC Wainwright Adjusts Talaris Therapeutics' Price Target to $12 From $18, Maintains Buy Rating

12:34 PM EDT, 10/24/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co

10-24 12:34 ET